Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
OsteopeniaOsteoporosis
Interventions
DRUG

Pamidronate

Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.

DRUG

Calcium and vitamin D

All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.

Trial Locations (2)

55454

University of Minnesota Amplatz Children's Hospital, Minneapolis

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02074631 - Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter